Your SlideShare is downloading. ×
0
Drug delivery via nanocapsules
Drug delivery via nanocapsules
Drug delivery via nanocapsules
Drug delivery via nanocapsules
Drug delivery via nanocapsules
Drug delivery via nanocapsules
Drug delivery via nanocapsules
Drug delivery via nanocapsules
Drug delivery via nanocapsules
Drug delivery via nanocapsules
Drug delivery via nanocapsules
Drug delivery via nanocapsules
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Drug delivery via nanocapsules

2,715

Published on

Drug delivery via nanocapsules

Drug delivery via nanocapsules

Published in: Education
1 Comment
5 Likes
Statistics
Notes
No Downloads
Views
Total Views
2,715
On Slideshare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
0
Comments
1
Likes
5
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Drug Delivery via Nanocapsules
  • 2. Nanocapsules
    • Shell of polymer nanoparticles
    • 3. Held together by electrostatic forces
    • 4. Drug kept inside until released
  • Benefits of Nanocapsules
    Receptors can be added without change to drug structure
    Minimize drug degradation
    Increase drug bioavailability
    Dosage for drugs can be decreased by 10,000 folds
  • 5. Benefits of Nanocapsules
    • Ultrasound-triggered release from capsule
  • Nanocapsule Shell Creation
    The capsules may be sized according to the specifics of capsulated molecules
    Colloidal particles are used for structural support.
    Shell is assembled using nanolayers of different components and functions.
    Adjusting shell thickness controls permeability, stability and degradation time, ultimately resulting in control of release time.
    Biodegradable shells may be assembled from polysaccharides and polypeptides (approved by FDA).
    Chitosan, alginate, dextran, and others polysaccharides.
    Gelatin, polylysine, polyglutamic acid, albumin, and other polypeptides.
  • 6. Calcium extraction (Core dissolution)
    Polymer, protein, DNA adsorbtion (embedding)
    Particle coating
    Compound Capture
    • Nearly 100% encapsulation efficiency using calcium carbonate microparticles.
    • 7. The calcium carbonate – compound microparticles are then encapsulated by a biodegradable shell.
    • 8. The encapsulation process is very mild and requires no chemical treatment.
    • 9. CaCO3 particles may be dissolved in very mild conditions. The compound remains inside capsules with no change of conformation or loss of activity.
  • 10. Encapsulation of Interferon
    Capture of Interferon using CaCO3
    Shell material:
    Dextran sulfate sodium salt alternating with Poly-L-lysine hydrochloride.
    First and last layers are composed of dextran sulfate.
    Total number of layers is 7.
    Overall encapsulation efficiency is 90%-95%(weight to volume). Size of capsules is 4-5 microns(subject to clinical/delivery needs and can be adjusted accordingly).
    This is a preliminary trial.
    Shell material, thickness and capsule size may be altered to meet pharmacokinetic demands and requirements.
  • 11. Safety of Nanoencapsulation
    Substances used for nanoencapsulation are biodegradable:
    Many are already FDA approved for human use in other applications.
    Subcutaneous injection:
    Results in degradation by macrophages.
    Local mild inflammation is noted on animal studies.
    No other significant reactions noted.
  • 12. Safety of Nanoencapsulation
    Vero 1 cells after 60hours incubation:
    Synthetic capsule
    No degradation
    Dextran Sulfate and
    poly-Argininecapsule
    Degradation
  • 13. Safety of Nanoencapsulation
    Mild tissue reaction.
    Good cellular uptake.
    Good capsule degradation.
  • 14. Rationaleof Nanoencapsulation
    Main market-hepatitis C
    Potential for expansion to treatment of hepatitis B
    Renewed interest in interferon therapy for hepatitis B
    Limited treatment duration
    Potential for eAbseroconversion
    Potential for loss of sAg
    Large market internationally

×